Pharmabiz10h
Enveda gets support from Sanofi to advance AI-driven drug discovery to clinical trials
Enveda gets support from Sanofi to advance AI-driven drug discovery to clinical trials: Boulder, Colorado Friday, February 28, 2025, 16:00 Hrs [IST] Enveda, a leading biotechnolog ...
Global drug giant boosts Boulder biotech's funding round to $150 million
The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...
The Pharma Letter1d
Sanofi investment latest validation of Enveda’s potential
Enveda, a Colorado-based biotech, has received a $20 million investment from French pharma major Sanofi. According to Enveda, ...
BizWest2d
Enveda adds millions to Series C haul
Boulder-based Enveda Biosciences, which uses machine learning to discover naturally occurring drug compounds, recently added ...
ENDPOINTS NEWS2d
Har­bour Bio­Med inks deal up to $395M; ORIC re­fines plans for two drugs
Harbour BioMed's subsidiary inks $395M deal, ORIC plans Phase 3 trials, Idorsia updates on deals, Sanofi backs Enveda, Zymeworks gets GSK milestone, BerGenBio ends study, Ignota raises £5.5M ...
Le Lézard2d
Pykus Therapeutics Expands Patent Portfolio for PYK-2101, a First-in-class Retinal Sealant Delivery Technology
Pykus Therapeutics, Inc. ("Pykus" or the "Company"), a medical technology company dedicated to improving the lives of patients with blinding eye diseases, today announced it has secured a new patent ...
Le Lézard2d
Sway Medical, Inc. Announces FDA 510(k) Clearance of its Comprehensive Concussion Management System
Sway Medical, Inc., the company that created the Mobile Concussion Management category, is proud to announce that it has received FDA 510(k) clearance as a Computerized Cognitive Assessment Aid for ...
Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M
Sanofi invests in Enveda, reaffirming the industry’s confidence in its AI drug discovery platform and ability to deliver differentiated medicines.
BizWest21d
Enveda: Dermatitis drug candidate could help treat asthma
BOULDER — Boulder-based Enveda Biosciences, which uses machine learning to discover naturally occurring drug compounds, plans to begin testing ENV-294, its leading drug candidate developed to treat ...
The Daily News23d
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic, ...
Yahoo Finance23d
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda has since identified asthma as a high-impact follow-on indication for ENV-294 following promising preclinical and translational data in asthma models. This expansion underscores the company ...
Joplin Globe23d
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic ...